BDSX is positioned in the Health Care sector. The balance sheet holds approximately $15.18 million in cash, alongside total assets of roughly $87.48 million. The company reports a net loss of approximately $35.27 million.
Biodesix holds a current price of $14.94 as of May 6, 2026, delivering a 32.56% increase on the day. Forward-looking probability metrics estimate that Biodesix carries 70% odds of experiencing financial distress. Over the last 90 trading days, it has demonstrated strong risk-adjusted performance. The performance scores are calculated from February 5, 2026 through May 6, 2026. Learn more.
Biodesix (BDSX) is listed on NASDAQ Exchange in USA. BDSX conducts business in the Health Care industry (Biotechnology sector). Market capitalization for Biodesix is about $113.91 million, leaving the company classified as small-cap across health care companies. Further market cap context comes from about 10.11 million shares outstanding, operating in the Health Care industry, and enterprise value near $167.78 million. BDSX has 174,016 shares sold short (2.55 days to cover). The gap between operating margin (-6.84%) and net margin (-39.85%) suggests significant non-operating costs such as interest or taxes. Biodesix is an operator in the health care segment where revenue is driven by core operating activity and end-market demand. BDSX reported previous year's revenue of $88.5 million. Net Loss for the year was -$35.27 million with profit before overhead, payroll, taxes, and interest of $71.78 million. Biodesix financial stability analysisOwnership Allocation Biodesix records a substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Biodesix Ownership Details
The core principle of portfolio investing is achieving the best return per unit of risk. Biodesix market risk premium measures the excess return above the risk-free rate for a long position in Biodesix.
The stock is undergoing above-average trading activities. Biodesix operates as a data-driven diagnostic solutions company in the United States. Biodesix was incorporated in 2005 and is headquartered in Boulder, Colorado. Biodesix employs 334 people. Headquarters are in 919 West Dillon Road, Louisville, CO, United States, 80027. Latest reported figures include market cap 113.91 million, P/B 44.57, P/S 1.29. As a micro-cap equity, Biodesix is evaluated across valuation, solvency, and efficiency signals. Fundamentals lead the analysis, with market-implied risk context alongside. The company is currently operating at a loss.
Methodology
Unless otherwise specified, financial data for Biodesix is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Biodesix (USA Stocks:BDSX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: The data underlying this report is sourced from public filings and market reference sources, including filings and releases published by U.S. Securities and Exchange Commission (SEC) via EDGAR. Some updates may be delayed based on publication cadence. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Biodesix may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board